Trial reportESMO open2026
Atezolizumab plus pertuzumab, trastuzumab, and chemotherapy in HER2-positive early breast cancer: final results of the phase III IMpassion050 trial.
Trial report in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03726879 (A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe IMpassion050 (NCT03726879) primary analysis showed similar pathologic complete response (pCR) rates with/without the addition of neoadjuvant atezolizumab to pertuzumab, trastuzumab, and chemotherapy in high-risk human epidermal growth factor receptor 2-positive early breast cancer in the intention-to-treat and programmed death-ligand 1 (PD-L1)-positive populations. Safety was consistent with other atezolizumab combination studies. We report final analysis results. PATIENTS AND
methodsPatients were randomized 1 : 1 to atezolizumab/placebo, plus pertuzumab, trastuzumab, and chemotherapy. Postsurgery, patients continued atezolizumab/placebo, plus pertuzumab and trastuzumab up to 1 year. Patients with residual disease could switch to trastuzumab emtansine plus atezolizumab/placebo for 14 cycles. Secondary endpoints included disease-free survival (DFS), event-free survival (EFS), and safety. Stratification factors were stage at diagnosis, hormone receptor (HR) status, and PD-L1 status.
resultsAt data cut-off (24 August 2023), 411/454 patients remained on-study (atezolizumab arm, 206/226; placebo arm, 205/228). Median follow-up was 44.2 and 43.4 months, respectively. Three-year EFS rates were 91.4% (atezolizumab) versus 89.0% {placebo [stratified hazard ratio 0.90, 95% confidence interval (CI) 0.50-1.59]}. Among patients who had surgery and postneoadjuvant therapy (n = 434), 3-year DFS rates were 92.9% (atezolizumab) versus 88.5% [placebo (hazard ratio 0.71, 95% CI 0.38-1.32)]. Numerically higher 3-year EFS and DFS rates with atezolizumab were seen in patients with PD-L1-negative status, HR-positive status, and stage T2 disease. Numerical DFS improvements with atezolizumab occurred regardless of pCR. Adverse events (AEs) of special interest in the adjuvant setting were more frequent with atezolizumab (59.4% versus 47.0%; none grade 5). The most common AEs (≥10% of patients in either arm) were radiation skin injury (24.0% versus 19.4%), arthralgia (20.7% versus 17.1%), and diarrhea (20.7% versus 13.4%).
conclusionsThere were no significant improvements in 3-year EFS (stratified hazard ratio: 0.90; 95% CI: 0.50-1.59) or DFS (unstratified hazard ratio: 0.71; 95% CI: 0.38-1.32) rates with the addition of atezolizumab. Safety remained consistent with the known profiles of the study drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.